Skip to content

Study · Animal study (in vivo) · rat · 2021

6 results

Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats.

Rasic D, Zenko Sever A, Rasic F, Strbe S, Rasic Z, Djuzel A, Duplancic B, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P, Sever M

Biomedicines13 Sept 2021Cited by 10 (Europe PMC)

PMID34572392 (opens in a new tab)PMCIDPMC8465604 (opens in a new tab)DOI10.3390/biomedicines9091206 (opens in a new tab)PepBankPUB-34572392
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

With the stable gastric pentadecapeptide BPC 157 therapy known to heal various both external and internal rat fistulas, we attempt to approach vesicovaginal fistula, continuous urine leaking through vagina, bladder stones, and a possible therapy solution among rats with well-formed 2 week-fistulas (vaginal/vesical 4 mm large defects) started with delayed therapy. Subsequent control fistula course (the subsequent 1, 2, 4, and 6 weeks) since beginning revealed the failed healing, fistula leaking, adhesions, urinary leaking through vagina, failed epithelization, collagenization, granulation tissue and neovascularization, increased inflammation, and necrosis. Thereby, the later intervals revealed the persistent inability to sustain even minimal volume, vesical, and vaginal defects and stone formation at the end of the experiment (fistula-time day 56). BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once time daily or perorally in drinking water until sacrifice) was initiated with a considerable delay (at 2 weeks after fistula formation). Already within 1 week therapy, all BPC 157 regimens stopped urinary leaking through vagina, reversed the otherwise resistant poor healing course to the increased epithelization, collagenization, granulation tissue and neovascularization, decreased inflammation, and decreased necrosis. Thereby, at later intervals, all BPC 157 rats exhibited a five times larger volume that can be sustained before leaking as in healthy, vesical, and vaginal defects completely closed and no stone formation. Thus, macro/microscopic and functional recovery, and counteracted stone formation. Concluding, BPC 157 therapy's beneficial effects resulted in healing and no stone formation, with µg- and ng-regimens, either given daily perorally in drinking water or intraperitoneally.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with 2-week vesicovaginal fistulas, all BPC‑157 regimens stopped urinary leaking through the vagina within 1 week of therapy.

    In plain wordsIn rats with a bladder-vagina fistula, BPC‑157 stopped urine leaking within one week of delayed treatment.

    Peptide
    BPC-157
    Outcome
    DecreaseUrinary leaking through the vagina
    Study

    ratn: not reported in source

    Established 2-week vesicovaginal fistula (4 mm vaginal/vesical defects)
    Comparator
    Untreated control fistula
    Outcome group
    Wound healing · Kidney and urinary
    Studied dose
    10 µg/kg, 10 ng/kg · intraperitoneal once daily, or peroral in drinking water · until sacrifice, started 2 weeks after fistula formationAs given in this study (rat).

    Source sentences

    Summary
    Already within 1 week therapy, all BPC 157 regimens stopped urinary leaking through vagina
    2 context sentences
    Summary · context
    With the stable gastric pentadecapeptide BPC 157 therapy known to heal various both external and internal rat fistulas, we attempt to approach vesicovaginal fistula, continuous urine leaking through vagina, bladder stones, and a possible therapy solution among rats with well-formed 2 week-fistulas (vaginal/vesical 4 mm large defects) started with delayed therapy.
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once time daily or perorally in drinking water until sacrifice) was initiated with a considerable delay (at 2 weeks after fistula formation).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with 2-week vesicovaginal fistulas, BPC‑157 reversed the poor healing course, with increased epithelization, collagenization, granulation tissue and neovascularization.

    In plain wordsIn rats with a bladder-vagina fistula, BPC‑157 reversed poor healing and increased tissue repair.

    Peptide
    BPC-157
    Outcome
    IncreaseEpithelization, collagenization, granulation tissue and neovascularization
    Study

    ratn: not reported in source

    Established 2-week vesicovaginal fistula (4 mm vaginal/vesical defects)
    Comparator
    Untreated control fistula
    Outcome group
    Wound healing · Kidney and urinary
    Studied dose
    10 µg/kg, 10 ng/kg · intraperitoneal once daily, or peroral in drinking water · until sacrifice, started 2 weeks after fistula formationAs given in this study (rat).

    Source sentences

    Summary
    reversed the otherwise resistant poor healing course to the increased epithelization, collagenization, granulation tissue and neovascularization
    2 context sentences
    Summary · context
    With the stable gastric pentadecapeptide BPC 157 therapy known to heal various both external and internal rat fistulas, we attempt to approach vesicovaginal fistula, continuous urine leaking through vagina, bladder stones, and a possible therapy solution among rats with well-formed 2 week-fistulas (vaginal/vesical 4 mm large defects) started with delayed therapy.
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once time daily or perorally in drinking water until sacrifice) was initiated with a considerable delay (at 2 weeks after fistula formation).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with 2-week vesicovaginal fistulas, BPC‑157 decreased inflammation and necrosis.

    In plain wordsIn rats with a bladder-vagina fistula, BPC‑157 reduced inflammation and tissue death.

    Peptide
    BPC-157
    Outcome
    DecreaseInflammation and necrosis
    Study

    ratn: not reported in source

    Established 2-week vesicovaginal fistula (4 mm vaginal/vesical defects)
    Comparator
    Untreated control fistula
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    10 µg/kg, 10 ng/kg · intraperitoneal once daily, or peroral in drinking water · until sacrifice, started 2 weeks after fistula formationAs given in this study (rat).

    Source sentences

    Summary
    decreased inflammation, and decreased necrosis.
    2 context sentences
    Summary · context
    With the stable gastric pentadecapeptide BPC 157 therapy known to heal various both external and internal rat fistulas, we attempt to approach vesicovaginal fistula, continuous urine leaking through vagina, bladder stones, and a possible therapy solution among rats with well-formed 2 week-fistulas (vaginal/vesical 4 mm large defects) started with delayed therapy.
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once time daily or perorally in drinking water until sacrifice) was initiated with a considerable delay (at 2 weeks after fistula formation).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with vesicovaginal fistulas, BPC‑157 rats sustained a volume five times larger before leaking, as in healthy rats.

    In plain wordsIn rats with a bladder-vagina fistula, treated animals held five times more volume before leaking, like healthy rats.

    Peptide
    BPC-157
    Outcome
    IncreaseVolume sustained before leaking
    Study

    ratn: not reported in source

    Established 2-week vesicovaginal fistula (4 mm vaginal/vesical defects)
    Comparator
    Untreated control fistula
    Outcome group
    Wound healing · Kidney and urinary
    Studied dose
    10 µg/kg, 10 ng/kg · intraperitoneal once daily, or peroral in drinking water · until sacrifice, started 2 weeks after fistula formationAs given in this study (rat).

    Source sentences

    Summary
    at later intervals, all BPC 157 rats exhibited a five times larger volume that can be sustained before leaking as in healthy
    2 context sentences
    Summary · context
    With the stable gastric pentadecapeptide BPC 157 therapy known to heal various both external and internal rat fistulas, we attempt to approach vesicovaginal fistula, continuous urine leaking through vagina, bladder stones, and a possible therapy solution among rats with well-formed 2 week-fistulas (vaginal/vesical 4 mm large defects) started with delayed therapy.
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once time daily or perorally in drinking water until sacrifice) was initiated with a considerable delay (at 2 weeks after fistula formation).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with vesicovaginal fistulas, vesical and vaginal defects completely closed in all BPC‑157 rats.

    In plain wordsIn rats with a bladder-vagina fistula, the defects closed completely with BPC‑157.

    Peptide
    BPC-157
    Outcome
    IncreaseClosure of vesical and vaginal defects
    Study

    ratn: not reported in source

    Established 2-week vesicovaginal fistula (4 mm vaginal/vesical defects)
    Comparator
    Untreated control fistula
    Outcome group
    Wound healing · Kidney and urinary
    Studied dose
    10 µg/kg, 10 ng/kg · intraperitoneal once daily, or peroral in drinking water · until sacrifice, started 2 weeks after fistula formationAs given in this study (rat).

    Source sentences

    Summary
    vesical, and vaginal defects completely closed and no stone formation.
    2 context sentences
    Summary · context
    With the stable gastric pentadecapeptide BPC 157 therapy known to heal various both external and internal rat fistulas, we attempt to approach vesicovaginal fistula, continuous urine leaking through vagina, bladder stones, and a possible therapy solution among rats with well-formed 2 week-fistulas (vaginal/vesical 4 mm large defects) started with delayed therapy.
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once time daily or perorally in drinking water until sacrifice) was initiated with a considerable delay (at 2 weeks after fistula formation).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with vesicovaginal fistulas, BPC‑157 rats had no stone formation, whereas controls formed stones by the end of the experiment.

    In plain wordsIn rats with a bladder-vagina fistula, BPC‑157 treated animals formed no bladder stones, unlike untreated controls.

    Peptide
    BPC-157
    Outcome
    DecreaseBladder stone formation
    Study

    ratn: not reported in source

    Established 2-week vesicovaginal fistula (4 mm vaginal/vesical defects)
    Comparator
    Untreated control fistula
    Outcome group
    Wound healing · Kidney and urinary
    Studied dose
    10 µg/kg, 10 ng/kg · intraperitoneal once daily, or peroral in drinking water · until sacrifice, started 2 weeks after fistula formationAs given in this study (rat).

    Source sentences

    Summary
    and no stone formation.
    3 context sentences
    Summary · context
    Thereby, the later intervals revealed the persistent inability to sustain even minimal volume, vesical, and vaginal defects and stone formation at the end of the experiment (fistula-time day 56).
    Summary · context
    With the stable gastric pentadecapeptide BPC 157 therapy known to heal various both external and internal rat fistulas, we attempt to approach vesicovaginal fistula, continuous urine leaking through vagina, bladder stones, and a possible therapy solution among rats with well-formed 2 week-fistulas (vaginal/vesical 4 mm large defects) started with delayed therapy.
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once time daily or perorally in drinking water until sacrifice) was initiated with a considerable delay (at 2 weeks after fistula formation).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.